Troglitazon
Prijeđi na navigaciju
Prijeđi na pretragu
![]() | |||
(IUPAC) ime | |||
---|---|---|---|
5-({4-[(6-hidroksi-2,5,7,8-tetrametil-3,4-dihidro-2H-1-benzopiran-2-il)metoksi]fenil}metil)-1,3-tiazolidin-2,4-dion | |||
Klinički podaci | |||
Robne marke | Noscal, Prelay, Resulin, Rezulin | ||
AHFS/Drugs.com | Monografija | ||
Identifikatori | |||
CAS broj | 97322-87-7 | ||
ATC kod | A10BG01 | ||
PubChem[1][2] | 5591 | ||
DrugBank | DB00197 | ||
ChemSpider[3] | 5389 | ||
ChEMBL[4] | CHEMBL9753 ![]() | ||
Hemijski podaci | |||
Formula | C24H27NO5S | ||
Mol. masa | 441.54 | ||
SMILES | eMolekuli & PubHem | ||
| |||
Fizički podaci | |||
Tačka topljenja | 184-186 °C (-119 °F) | ||
Farmakokinetički podaci | |||
Poluvreme eliminacije | 16-34 sati | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | |||
Način primene | Oralno |
Troglitazon je povučen sa tržišta 2000. godine uzled povećanog rizika od hepatotoksičnosti. On je zamenjen pioglitazonom i rosiglitazonom.[5][6][7]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P: Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab. 2001 Jul;86(7):3250-6. PMID 11443197
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
- ↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.